Phase 2 Trial of TAK-700 (Also Known as Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Orteronel (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 06 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov.
- 11 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.